Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Precision BioSciences, Inc. (NASDAQ:DTIL), a biotechnology company currently valued at $56 million, held its annual shareholder meeting on May 28, 2025, as detailed in a recent SEC filing. The meeting saw a turnout of approximately 71% of the company’s outstanding common stock, amounting to 7,506,352 shares either present in person or represented by proxy. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 6.62, though it faces profitability challenges with negative earnings in the last twelve months.Want deeper insights? InvestingPro subscribers have access to over 10 additional key metrics and analysis tips for Precision BioSciences.
The agenda included several key proposals amid challenging financial conditions, with the company’s revenue expected to decline in 2025. The election of two Class III directors was on the docket, with Kevin J. Buehler and Shari Lisa Piré both securing positions to serve until the 2028 annual meeting. Buehler received 2,987,931 votes in favor, while Piré garnered 2,953,557 votes. Both directors saw a significant number of broker non-votes, totaling 3,753,012.
Shareholders also ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. This proposal received 7,445,447 votes in favor, 12,604 against, and 48,301 abstentions.
Additionally, an advisory vote on executive compensation passed with 3,389,745 votes for, 261,406 against, and 102,189 abstentions. The board decided to conduct annual advisory votes on executive compensation moving forward.
A proposal to amend the Certificate of Incorporation to align with Delaware law changes regarding officer exculpation did not pass. Despite receiving 95% of the votes cast in favor, the proposal failed to achieve the necessary majority of all outstanding shares as of April 8, 2025.
These results were disclosed in a filing submitted to the SEC, providing transparency to investors and stakeholders regarding the company’s governance and financial oversight decisions. While the company holds more cash than debt on its balance sheet, InvestingPro analysis indicates rapid cash burn and projects continued challenges in achieving profitability this year.
In other recent news, Precision BioSciences has made significant strides in its gene editing therapies. The U.S. Food and Drug Administration (FDA) granted Fast Track designation to Precision BioSciences’ lead program, PBGENE-HBV, aimed at potentially curing chronic hepatitis B. This designation is intended to expedite the development process for treatments addressing serious conditions. The company is conducting a global Phase 1 trial, ELIMINATE-B, across several countries, with promising initial safety and efficacy results reported. Additionally, the FDA has cleared an Investigational New Drug (IND) application for PBGENE-HBV, allowing the trial to expand into the United States. H.C. Wainwright reaffirmed its Buy rating and $60 price target for Precision BioSciences, following the presentation of promising preclinical data for another gene editing candidate, PBGENE-DMD, targeting Duchenne muscular dystrophy. These developments reflect Precision BioSciences’ ongoing efforts to address unmet medical needs through its ARCUS genome editing platform. The company’s collaboration with Acuitas Therapeutics further supports the development of its potentially transformative treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.